LionEye Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

LionEye Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,100,000	Closed	-$65M	–	46
2015 Q2	$65M	Buy	1,100,000 +393,500	+56%	+$24.3M	2.52%	10
2015 Q1	$44M	Buy	+706,500	New	+$41.1M	1.77%	12

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LionEye Capital Management's TEVA Position: Q3 2015 in Review

LionEye Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2015, closing a stake of 1,100,000 shares — an estimated $65M sold.

LionEye Capital Management first reported a position in TEVA in Q1 2015 and held it in 2 quarters. The position peaked at $65M in Q2 2015. 823 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

LionEye Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
LionEye Capital Management sold 1,100,000 Teva Pharmaceuticals shares in Q3 2015, an estimated $65M.
LionEye Capital Management first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 2 quarters.
LionEye Capital Management's Teva Pharmaceuticals position peaked at $65M in Q2 2015.
823 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2015.

Based on LionEye Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.